Fig. 1: Epigenome-wide association studies on DNA methylation and CAD adverse outcomes.
From: DNA methylation predicts adverse outcomes of coronary artery disease
a Study design. Patients in the discovery and the validation sets were enrolled from one and three medical centers in China, respectively. The sample size for discovery and validation cohorts were 405 and 528, respectively. Baseline characteristics were collected during enrollment. DNA methylation of peripheral blood leukocytes was measured by Illumina MethylationEPIC 850 K BeadChip. Differential methylation sites associated with death were identified, prognostic risk models were built, and lastly, biological mechanisms were inferred. This graph was created in BioRender. Pan, C. (2025) https://BioRender.com/mao524f. In the boxplot of panels, hinges indicate the 25th, 50th, and 75th percentiles, whiskers indicate 1.5× interquartile ranges. b EWAS of death performed in the discovery set. Red line and blue line mark the P-value thresholds, with the former from Bonferroni correction, and the latter from false discovery rate correction. CAD coronary artery disease, PLR platelet-lymphocyte ratio, FIB fibrinogen, SII systemic immune-inflammation index, HDLC high-density lipoprotein cholesterol, LVEF left ventricular ejection fraction, LVMI left ventricular mass index, DMP differential methylation probe, TF transcriptional factor, IL interleukin.
